JP2022541657A5 - - Google Patents

Info

Publication number
JP2022541657A5
JP2022541657A5 JP2022505282A JP2022505282A JP2022541657A5 JP 2022541657 A5 JP2022541657 A5 JP 2022541657A5 JP 2022505282 A JP2022505282 A JP 2022505282A JP 2022505282 A JP2022505282 A JP 2022505282A JP 2022541657 A5 JP2022541657 A5 JP 2022541657A5
Authority
JP
Japan
Prior art keywords
fusion protein
variant
composition
protein according
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022505282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541657A (ja
JP7483857B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043416 external-priority patent/WO2021021606A1/en
Publication of JP2022541657A publication Critical patent/JP2022541657A/ja
Publication of JP2022541657A5 publication Critical patent/JP2022541657A5/ja
Priority to JP2024074388A priority Critical patent/JP7850199B2/ja
Application granted granted Critical
Publication of JP7483857B2 publication Critical patent/JP7483857B2/ja
Priority to JP2026064900A priority patent/JP2026100003A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022505282A 2019-07-26 2020-07-24 インターロイキン-2作用物質およびその使用 Active JP7483857B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024074388A JP7850199B2 (ja) 2019-07-26 2024-05-01 インターロイキン-2作用物質およびその使用
JP2026064900A JP2026100003A (ja) 2019-07-26 2026-04-10 インターロイキン-2作用物質およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962879137P 2019-07-26 2019-07-26
US62/879,137 2019-07-26
US202062983061P 2020-02-28 2020-02-28
US62/983,061 2020-02-28
PCT/US2020/043416 WO2021021606A1 (en) 2019-07-26 2020-07-24 Interleukin-2 agents and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074388A Division JP7850199B2 (ja) 2019-07-26 2024-05-01 インターロイキン-2作用物質およびその使用

Publications (3)

Publication Number Publication Date
JP2022541657A JP2022541657A (ja) 2022-09-26
JP2022541657A5 true JP2022541657A5 (cg-RX-API-DMAC7.html) 2023-11-16
JP7483857B2 JP7483857B2 (ja) 2024-05-15

Family

ID=72179191

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022505282A Active JP7483857B2 (ja) 2019-07-26 2020-07-24 インターロイキン-2作用物質およびその使用
JP2024074388A Active JP7850199B2 (ja) 2019-07-26 2024-05-01 インターロイキン-2作用物質およびその使用
JP2026064900A Pending JP2026100003A (ja) 2019-07-26 2026-04-10 インターロイキン-2作用物質およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024074388A Active JP7850199B2 (ja) 2019-07-26 2024-05-01 インターロイキン-2作用物質およびその使用
JP2026064900A Pending JP2026100003A (ja) 2019-07-26 2026-04-10 インターロイキン-2作用物質およびその使用

Country Status (14)

Country Link
US (3) US12084484B2 (cg-RX-API-DMAC7.html)
EP (1) EP4004025A1 (cg-RX-API-DMAC7.html)
JP (3) JP7483857B2 (cg-RX-API-DMAC7.html)
KR (1) KR102943539B1 (cg-RX-API-DMAC7.html)
CN (2) CN114450298B (cg-RX-API-DMAC7.html)
AU (1) AU2020323893B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001415A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147757A1 (cg-RX-API-DMAC7.html)
IL (1) IL290118A (cg-RX-API-DMAC7.html)
MX (1) MX2022001061A (cg-RX-API-DMAC7.html)
MY (1) MY209471A (cg-RX-API-DMAC7.html)
PH (1) PH12022550165A1 (cg-RX-API-DMAC7.html)
TW (2) TW202604940A (cg-RX-API-DMAC7.html)
WO (1) WO2021021606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) * 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
BR112022017656A2 (pt) * 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
WO2022159590A1 (en) 2021-01-20 2022-07-28 Visterra, Inc. Interleukin-2 mutants and uses thereof
CN112961245B (zh) * 2021-02-24 2023-07-25 重庆精准生物技术有限公司 一种靶向cd96的双特异性抗体及其制备方法和用途
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
EP4376870A4 (en) * 2021-07-28 2025-07-23 Anwita Biosciences Inc INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
CA3243493A1 (en) * 2022-02-11 2023-08-17 Visterra, Inc. INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN114848808B (zh) * 2022-03-24 2023-04-25 四川大学 基于阳离子脂多肽及细胞因子的免疫增强剂及制法、应用
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
CN115850436B (zh) * 2022-10-14 2026-02-03 海徕科(北京)生物技术有限公司 白介素2突变体及其应用
WO2024146575A1 (zh) * 2023-01-04 2024-07-11 北京晶泰科技有限公司 白细胞介素-2变体及其应用
EP4766723A1 (en) * 2023-08-23 2026-07-01 Depth Charge Ltd VARIANT PROTEINS OF INTERLEUKIN-2 THAT FACILITATE COVALENT CHEMICAL CONJUGATION AND THEIR USES
CN119345372A (zh) * 2024-10-28 2025-01-24 北京大学人民医院 Cd132在治疗aml中的应用
WO2026154422A1 (en) * 2025-01-17 2026-07-23 Otsuka Pharmaceutical Company, Ltd. Il-2-fc fusion protein for use in treating autoimmune diseases

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4908433A (en) 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0262802A3 (en) 1986-09-01 1990-01-31 Takeda Chemical Industries, Ltd. Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
CA2100671C (en) 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
CA2456470A1 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
KR20070003934A (ko) 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
KR100873651B1 (ko) 2008-08-21 2008-12-11 김광한 잔디 식재기
KR101094207B1 (ko) 2008-08-21 2011-12-14 연세대학교 산학협력단 T1―t2 이중방식 mri 조영제
KR101111286B1 (ko) 2008-08-22 2012-03-14 한국생산기술연구원 발포체, 이 발포체의 제조장치, 이 발포체를 이용한 발포금속의 제조방법 및 발포금속 제조장치
CN102197027A (zh) 2008-08-22 2011-09-21 株式会社Lg化学 用于有机电子器件的材料以及使用所述材料的有机电子器件
WO2010021520A2 (ko) 2008-08-22 2010-02-25 엘지전자 주식회사 동기 채널 전송 방법
KR100996532B1 (ko) 2008-08-22 2010-11-24 주식회사 엠아이텍 탄소나노튜브 기반 바이오센서에서 링커와 스페이서를 이용한 민감도 증가 방법
WO2010021527A2 (ko) 2008-08-22 2010-02-25 Jung Tae Woo 영상에 포함된 객체를 색인하는 시스템 및 방법
WO2010021525A2 (en) 2008-08-22 2010-02-25 Lg Electronics Inc. A method for processing a web service in an nrt service and a broadcast receiver
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
US9669071B2 (en) 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
EP3443979B2 (en) 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
AU2016246152A1 (en) 2015-04-10 2017-11-02 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
RU2611685C2 (ru) 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20240115933A (ko) 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US20210277085A1 (en) 2017-05-24 2021-09-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3720871A4 (en) 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
KR20240115352A (ko) 2017-12-06 2024-07-25 팬디온 오퍼레이션스, 인코포레이티드 Il-2 뮤테인 및 그 용도
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたil-2 fc融合タンパク質
US12522640B2 (en) 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
WO2022159590A1 (en) 2021-01-20 2022-07-28 Visterra, Inc. Interleukin-2 mutants and uses thereof
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
CA3243493A1 (en) 2022-02-11 2023-08-17 Visterra, Inc. INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Similar Documents

Publication Publication Date Title
ES2773527T3 (es) Receptor quimérico para antígeno
JP2023524054A5 (cg-RX-API-DMAC7.html)
JP2023544834A5 (cg-RX-API-DMAC7.html)
JP2021520198A5 (cg-RX-API-DMAC7.html)
JP2018171063A5 (cg-RX-API-DMAC7.html)
JP2025184979A5 (cg-RX-API-DMAC7.html)
Tian et al. Three TNFR-binding domains of PGRN act independently in inhibition of TNFα binding and activity
JP2013513377A5 (cg-RX-API-DMAC7.html)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
JP2020528743A5 (cg-RX-API-DMAC7.html)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
CA3140064A1 (en) Lockr-mediated recruitment of car t cells
JP2012522501A5 (cg-RX-API-DMAC7.html)
CN102665754A (zh) 衍生自il-2的免疫调节多肽及其在治疗癌症和慢性感染中的用途
JP2015501156A5 (cg-RX-API-DMAC7.html)
CN102482324A (zh) 能够抑制自身免疫、炎症和癌症进程的新型趋化因子结合多肽
JP2023534924A5 (cg-RX-API-DMAC7.html)
WO2002086133A1 (fr) Additifs de milieu et milieux de culture de cellules animales
WO2022032660A1 (zh) 新型冠状病毒rbd融合蛋白
CN113321736B (zh) 一种长效化白介素15融合蛋白及其制备方法和应用
JP2025506173A5 (cg-RX-API-DMAC7.html)
JP2025500465A5 (cg-RX-API-DMAC7.html)
CN104745596B (zh) 靶向肝癌细胞的细胞制备物
CN121013905A (zh) 已经引入至编码特异性结合于TNFR2的Stefin A蛋白变体或包括该蛋白变体的融合蛋白的核酸中的基因修饰的细胞,及其用途
CA2446260A1 (en) Novel expression vectors and uses thereof